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Oral zeranol shortens the prolonged bleeding time of uremic
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Oral zeranol shortens the prolonged bleeding time of uremic rats.
Intravenous conjugated estrogens reduce the prolonged bleeding time in
uremic patients and in a rat model of uremia. However, estrogens have
major side effects related to their hormonal activity. We investigated
whether a f3-resorcylic acid lactone, zeranol (a compound with close
spatial similarity to estrogens but with a weak estrogenic activity),
improves primary hemostasis in uremic rats and whether the effect is
mediated by estrogen receptors. The results showed that single oral
administration of zeranol significantly (P < 0.01) shortened the bleeding
time of uremic rats, 20 mg/kg being the minimum effective dose. This
effect was long-lasting (72 hours). The dose of 30 mg/kg zeranol
reproduced the pattern observed after 20 mg/kg but bleeding time
values were still significantly (P < 0.01) shortened 96 hours after the
administration. No changes in hematocrit, platelet and leukocyte count,
and serum creatinine were detected after zeranol administration. When
uremic rats were pre-treated orally with two estrogen receptor antago-
nists, tamoxifen and clomiphene (3 mg/kg), zeranol did not shorten the
bleeding time, thus suggesting that the hemostatic effect of zeranol was
due to an estrogen receptor-mediated mechanism. These results might
have important future implications for the management of uremic
bleeding in humans.
Renal insufficiency is associated with a bleeding tendency
[1—4], due to a complex platelet dysfunction [1, 4—7], which
correlates with a prolonged skin bleeding time [81. Modern
techniques for the management of uremia have definitely re-
duced the incidence of severe bleeding episodes in renal failure
patients, but hemorrhages still represent a major clinical prob-
lem for patients undergoing surgery or invasive procedure [91.
Several approaches have been proposed that shorten the pro-
longed bleeding time in uremia [reviewed in 9], among which
conjugated estrogen infusions, by virtue of their long duration
of action, are of particular value when a long-lasting hemostatic
'competence' is required [10—121. Recently a rat model of
chronic uremia has been established in which bleeding time is
prolonged and conjugated estrogens effective [13]. This model
establishes that the key component of the conjugated estrogen
mixture effective in shortening bleeding time is 17/3-estradiol,
and that its activity on primary hemostasis is mediated by an
estrogen receptor mechanism [14]. Estrogens, however, have
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major side effects related to their hormonal activity, including
nausea, breast enlargement, a sense of congestion and heavi-
ness in the lower abdomen, hyperplasia of the endometrium and
endometrial carcinoma [15—17]. Thus, the search for molecules
with a hemostatic activity comparable to conjugated estrogens
but devoid of side effects is of great importance to the future
management of uremic patients with bleeding. In this context
zeranol [18], a natural myco-estrogen with weak hormonal
activity [19], appears to be a potentially interesting candidate.
Zeranol (Fig. 1) is a $-resorcylic acid lactone employed as a
growth promoter in veterinary practice, and is remarkably less
active than estradiol as far as estrogenic potency [18]. Actually,
Everett et al [20], comparing estrogenic potencies of resorcylic
acid lactones and 17j3-estradiol in sexually immature female
rats, showed that the oral zeranol administration was 150 times
less active in uterotrophic response than estradiol. An addi-
tional important point is that this molecule is chemically unre-
lated to steroids but has a close tridimentional structure to
estradiol, because it is of similar length and lipophylicity [18].
This remarkable spatial similarity explains the affinity of zera-
nol for estrogen receptors [21—241. This permits a discrimination
between affinity for estrogen binding sites and a steroidal-like
structure as the key determinant of the 'hemostatic' activity of
a molecule.
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Here we investigated whether zeranol given in a single oral
dose improved primary hemostasis in the rat model of chronic
renal uremia, and whether its effect was inhibited by estrogen
receptor blocking.
Methods
Dose-effect study of zeranol on bleeding time in rats with
renal mass reduction
Male Sprague-Dawley rats (Charles River Italia S.p.A.,
Calco, Italy), weighing 300 to 350 g at the start of the experi-
ment, were used. Animals were fed a standard rat chow
(Altromin Rieper, Vandoies, Italy) and had free access to tap
water. Renal mass was reduced by removing the right kidney
and infarcting approximately five-sixths of the left kidney by
ligation of two or three extrarenal branches of the main renal
artery, according to the method of Olson et al [25], with the rats
under ether anesthesia.
Four weeks after the ablative procedure 29 rats were subdi-
vided as follows: group 1, eight rats which were given 10 mg/kg
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Fig. 1. Chemical structure of zeranol 16-(6,1O-dihydroxyundecyl)-f3-
resorcyl acid lactone].
zeranol orally (Compagnia di Ricerca Chimica, Udine, Italy)
dissolved in I ml of 0.5% carboxy methyl cellulose (Sigma
Chemical Co., St. Louis, Missouri, USA); group 2, eight rats
which were given 20 mg/kg zeranol orally; group 3, eight rats
which were given 30 mg/kg zeranol orally; and group 4, five rats
which received the vehicle alone. An additional group of 15
sham-operated rats (laparotomy and manipulation of renal
pedicles but without destruction of renal tissue) were divided in
three groups (N = 5) and given the different doses of zeranol
orally. Bleeding times were measured before (time 0) and at
different time intervals after drug or vehicle administration.
Effect of zeranol on hematocrit, platelet and leukocyte count,
and serum creatinine in rats with renal mass reduction
To verify whether zeranol administration could affect hema-
tological and renal function parameters, in six rats with renal
mass reduction we measured hematocrit, platelet and leukocyte
count, and serum creatinine before and 24, 48, 72 and 96 hours
after zeranol administration (20 mg/kg). The same parameters
were measured in six sham-operated rats before and 24 hours
after zeranol (20 mg/kg).
Effect of estrogen receptor antagonists on bleeding time in
uremic rats treated with zeranol
To evaluate whether zeranol's effect on bleeding time was
mediated by a receptor mechanism, we gave two estrogen
receptor antagonists to uremic rats, namely tamoxifen and
clomiphene. These compounds are known to bind to cytoplas-
mic estrogen receptors, so that the modified complex is trans-
located into the nucleus. A competition for estrogen binding
sites results in a diminished amount of estrogen receptor
available and explains their antiestrogenic activity [15].
Experiments were carried out in two groups of rats with renal
mass reduction (N = 5 each), receiving orally 3 mg/kg tamox-
ifen (Nolvadex, ICI-Pharma S.p.A., Milan, Italy) or 3 mg/kg
clomiphene (Clomid, Gruppo Lepetit, S.p.A., Milan, Italy) in 1
ml of 0.5% carboxy methyl cellulose. The doses of tamoxifen
and clomiphene were chosen taking into account the results of
a previous study [14]. Bleeding times were measured before and
24 hours after estrogen receptor antagonists in order to evaluate
possible influences of estrogen receptor antagonist itself on
bleeding time. Subsequently, zeranol (20 mg/kg) was orally
administered and 24 hours later bleeding time was again mea-
sured.
Bleeding time
Bleeding time was performed in unanesthetized animals to
avoid possible influence of anesthesia on blood-vessel interplay
and interactions between anesthetics and drugs to be adminis-
tered [261. Rats were placed iii a plastic cylinder with several
openings from one of which the rat's tail emerged. A standard-
ized Simplate II device (General Diagnostic, Milan, Italy) was
used. The device was applied longitudinally on the dorsal part
of the tail between 6 and 9 cm from the tip, taking care to avoid
large veins. Tails of rats were left in the air and the animals were
maintained at room temperature. Bleeding time was measured
from the moment the tail was incised until bleeding stopped
completely (no rebleeding within 30 seconds). Bleeding time
was expressed in seconds (normal range: 80 to 120 seconds).
Laboratory tests
Hematocrit values were determined by routine laboratory
methods. Platelets and leukocytes were counted by phase-
contrast microscopy. Serum creatinine was measured by the
alkaline picrate method [271.
Statistical analysis
Results are expressed as mean SD. Statistical analysis was
performed by using paired Student's (-test or one-way analysis
of variance by Duncan test for multiple comparisons as appro-
priate [28]. Statistical significance level was defined asP < 0.05.
Results
Effect of zeranol administration on bleeding time in uremic
rats
As previously reported [13] uremic rats had a significant (P <
0.01) prolongation of bleeding time with respect to sham oper-
ated rats [uremics (N = 24) 202 34 sec; sham (N = 15) 95
16 sec].
Figure 2 shows the effect of different single doses of zeranol
on bleeding time in uremic rats at different time intervals from
drug administration. The dose of 10 mg/kg zeranol did not affect
bleeding time as indicated by values recorded at 24 and 48
hours. At variance, 20 mg/kg zeranol significantly (P < 0.01)
shortened bleeding time. This effect lasted 72 hours. The
bleeding time values returned to normal range in five of eight
rats at 24 hours, in seven of eight rats at 48 hours and in one of
eight rats at 72 hours. Ninety-six hours after zeranol adminis-
tration bleeding time values were again comparable to the basal
ones. Thirty mg/kg zeranol significantly (P < 0.01) reduced the
bleeding time, and the effect lasted for 96 hours, with a
significant (P < 0.01) shortening with respect to basal values.
The bleeding time values returned to normal range in seven of
eight rats at 24 hours, in all rats at 48 hours, in six of eight rats
at 72 hours and in five of eight rats at 96 hours. The adminis-
tration of vehicle alone had no effect on bleeding time in uremic
rats (before vehicle: 193 26; 24 hours after vehicle: 192 11
sec). In sham operated animals different doses of zeranol had no
effect on bleeding time values (10 mg/kg: before: 95 21, 24
hours after: 91 10; 20 mg/kg: before: 92 10, 24 hours after:
85 11; 30 mg/kg: before: 98 16, 24 hours after: 99 9 sec).
Effect of zeranol on hematocrit, platelet and leukocyte count
and serum creatinine in uremic rats
Twenty mg/kg, that is, the minimum dose which effectively
shortened the prolonged bleeding time of uremic rats, was used
to test whether zeranol affected hematological or renal function
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Fig. 2. Effect of single oral zeranol administrations on bleeding time in
uremic rats at different time intervals. A. 10 mg/kg. B. 20 mg/kg. C. 30
mg/kg. Results are expressed as mean SD. * P < 0.01 as compared
with basal bleeding time measurements.
parameters in rats with renal mass reduction. As shown in
Table 1, no significant changes were observed in hematocrit
values, platelet and leukocyte counts, as well as in serum
creatinine measured before and at different time intervals after
zeranol. Similarly, in sham operated animals zeranol treatment
had no effect on hematocrit (before zeranol: 48 2 and at 24
hours: 49 2%), platelet count (before zeranol: 89 5 and at
24 hours: 88 4 x 104/1.d), leukocyte count (before zeranol:
11.9 1.9 and at 24 hours: 11.7 1.5 x 103/jsl) and serum
creatinine (before zeranol: 0.56 0.02 and at 24 hours: 0.58
0.04 mg/dl).
Effect of estrogen receptor antagonists on bleeding time in
uremic rats treated with zeranol
As shown in Figure 3, the administration of 3 mg/kg tamox-
ifen blocked the zeranol effect on shortening the bleeding time.
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0 43 2 88 6 14.9 3.5 1.04 0.17
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Fig. 3. Effect of estrogen receptor antagonists—tamoxifen (A) and
clomiphene (B)—on bleeding time in uremic rats receiving zeranol (20
mg/kg). Zeranol was given 24 hours after tamoxifen or clomiphene
administration. Results are expressed as mean SD.
Similar results were obtained when the other estrogen receptor
antagonist, clomiphene, was used. These findings support the
possibility that an estrogen receptor-mediated mechanism is
responsible for the hemostatic effectiveness of zeranol.
Discussion
The model of extensive renal mass ablation in the rat is of
particular importance in studying the abnormal primary hemo-
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Table 1. Effect of zeranol administration (20 mg/kg) on hematocrit,
platelet and leukocyte count and serum creatinine in uremic rats
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stasis associated with uremia, since bleeding time is prolonged
as it is in humans, and this abnormality is corrected by
conjugated estrogens [13]. In the above rat model the effect of
conjugated estrogens, given as a single injection, on bleeding
time lasts for 48 hours (131, and is mainly attributable to
17/3-estradiol, one of the components of the mixture [14]. In
patients with chronic renal failure, a long-lasting effect on
bleeding time was obtained after five infusions (0.6 mg/kg) of
conjugated estrogens spaced 24 hours apart. The effect on
shortening the bleeding time lasted for 14 days or more,
documenting a cumulative effect of repeated dosing of conju-
gated estrogens [12].
With the present study we have documented that zeranol is
also effective in shortening the prolonged bleeding time of
uremic rats. As for the estrogen mixture the effect of zeranol is
long-lasting. Actually, a significant shortening of bleeding time
was still observed 72 hours after 20 mg/kg and 96 hours after 30
mg/kg zeranol administration.
Since estrogen treatment may be associated with potential
complications, particularly carcinoma and gynecomastia [15—
17], the present finding of the hemostatic effectiveness of
zeranol, a natural myco-estrogen with weak hormonal activity
[18, 20], seems to be of great importance. However, careful
studies are required to exclude that a long-term zeranol treat-
ment may be associated with relevant side effects linked to the
estrogenic properties of the molecule. In a lifetime oral carci-
nogenicity study of zeranol in the rat [29] no evidence of any
carcinogenic effect was reported, only mild endocrine-associ-
ated changes were observed in some organs. Endometrial
changes have been described in long-term feeding studies of
zeranol in the beagle dog and in the rhesus monkey [291.
However, no carcinogenic effect was observed in these animals
after seven to ten years of zeranol administration. As far as
genotoxic activity of zeranol, negative results have been re-
ported in bone-marrow cytogenetic tests and mouse lymphoma
forward mutation assays [30].
The fact that zeranol is active on uremic bleeding after oral
administration could be relevant in the peculiar context of
uremia, since most of these patients often experience minor
bleeding (that is, epistaxis, gingival bleeding and menorrhagia)
that might well be self-managed at home by an orally active
compound as opposed to drugs which have to be given intra-
venously.
The present study also documented that the activity of oral
zeranol on uremic bleeding in the rat is likely mediated by its
binding to estrogen receptors [21—24]. Indeed, when uremic rats
were pre-treated with two estrogen-receptor antagonists, ta-
moxifen and clomiphene, zeranol did not shorten the bleeding
time. These data are in good agreement with previous findings
that specific estrogen-receptor antagonists neutralized the he-
mostatic effect of conjugated estrogen mixture or its active
components (17/3-estradiol and estrone sulfate) in uremic rats
[14]. Moreover, it has been documented that zeranol and its
metabolite compete with estradiol for binding to cytoplasmic
estrogen receptors in uterus [211, and mammary gland [22] of
the rat, as well as in bovine liver cells [23] and in human breast
cancer cells [241.
The proposed estrogen mechanism of action suggests that
estrogens enter the cell and bind with high-affinity receptor
proteins on the cytosol [311. The binding of estrogens to
estrogen-responsive cells induces a change in the receptor
which promotes the translocations of the complex into the
nucleus with the subsequent induction of specific proteins [321.
Since like estradiol, zeranol induces the translocation of estro-
gen receptor sites to the nucleus [23, 33], one can postulate that
the 'hemostatic' effect of zeranol is due to an identical mecha-
nism or possibly to the induction of a different protein. Which is
the receptor bearing cell that represents the target for the effect
of estrogen and zeranol on primary hemostasis is open to
speculation. Actually, among cells involved in primary hemo-
stasis, possible candidates are endothelial or white blood cells
that both possess estrogen receptors [34, 35]. Further studies
will properly clarify this important issue.
In conclusion, we have documented that zeranol: 1) has a
long-lasting effect on the abnormal hemostasis of uremic rats; 2)
is active per os after a single administration; 3) its activity is
related to its binding to estrogen receptors.
These results have obvious implications for the future man-
agement of uremic bleeding in humans.
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